title: [Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of intravitreal ranibizumab (Lucentis) in the first-line treatment of choroidal neovascularization (CNV) secondary to pathological myopia.
  
  
  METHODS
  Consecutive series of patients with primary subfoveal CNV secondary to pathological myopia treated with intravitreal ranibizumab 0.5mg (0.05ml) were included prospectively in this study. Best-corrected visual acuity, fundus examination, fluorescein angiography, optical coherence tomography, and the presence of metamorphopsia were assessed at baseline and then monthly. Indications for retreatment were persistent leakage from CNV shown on FA and/or evidence of CNV activity on OCT.
  
  
  RESULTS
  Eight eyes of seven patients were followed from November 2007 to April 2009. The mean age was 61 years. None of these eyes had been treated previously with photodynamic therapy or direct photocoagulation. The mean spherical equivalent refractive error was -10.75 (range: -7.75 to -15.75). Follow-up was 12 months or more for all patients except one (3 months). The mean number of intravitreal injections administered for each patient was 1.5 (range: 1-4). Six eyes received one ranibizumab injection, one eye received two, and one eye received four. Four eyes demonstrated a gain in visual acuity, three eyes stabilization, and one eye vision loss. No injection complications or drug-related side effects were noted during the follow-up period.
  
  
  CONCLUSIONS
  In this small series of eyes with limited follow-up, intravitreal ranibizumab was a safe and effective treatment for CNV secondary to pathological myopia, resulting in functional and anatomic improvements.
authors.affiliation: Service d'ophtalmologie, hospices civils de Lyon, hôpital Edouard-Herriot, université Lyon 1, 5, place d'Arsonval, 69437 Lyon cedex 03, France. pierre-loic.cornut@chu-lyon.fr
authors.forename: P-L
authors.initials: PL
authors.lastname: Cornut
authors.forename: M
authors.initials: M
authors.lastname: Poli
authors.forename: A
authors.initials: A
authors.lastname: Feldman
authors.forename: H
authors.initials: H
authors.lastname: El Chehab
authors.forename: B
authors.initials: B
authors.lastname: Swalduz
authors.forename: C
authors.initials: C
authors.lastname: Burillon
authors.forename: P
authors.initials: P
authors.lastname: Denis
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications*; D011446:Prospective Studies; D000069579:Ranibizumab; D013997:Time Factors; D014822:Vitreous Body
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab